retatrutide type 2 diabetes phase 2 results Lilly's triple agonist achieves 16.8% weight loss in 3 trial Retatrutide Clinical Trial – My
Description
j , Change in body weight
Hypoglycaemia is only a potential issue if GLP-1 analogues are combined with a sulfonylurea or insulin
The STEP 1 trial data revealed that 38% of weight lost on semaglutide came from lean body mass, not fat
Previous weight-loss medications often had disagreeable side effects, tolerability issues, and safety concerns
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
What to Expect once starting
